Gilead Sciences Q2 26 Earnings
Revenue: $7.80B (est $7.40B) Adjusted Loss/Share: $6.75 (est loss/share $7.17) Trodelvy Revenue: $457M (est $423.2M) Biktarvy Revenue: $3.77B (est $3.60B) Veklury Revenue: $23M (est $98.1M) Sees FY Product Sales: $30.1B To $30.4B (est $30.06B) Sees FY Adjusted Loss/Share: 30c To 65c Sees FY Veklury Revenue: $300M, Saw $600M
Story updates
08:09:00 PM UTC
SquawkNews
GILD GILEAD SCIENCES POSTED Q2 REVENUE OF $7.80 BLN, ABOVE THE $7.40 BLN ESTIMATE, WITH AN ADJUSTED LOSS PER SHARE OF $6.75, NARROWER THAN THE EXPECTED $7.17 LOSS, AS BIKTARVY REVENUE OF $3.77 BLN AND TRODELVY REVENUE OF $457 MLN BOTH BEAT ESTIMATES WHILE VEKLURY REVENUE OF $23 MLN MISSED THE $98.1 MLN ESTIMATE.
08:09:07 PM UTC
SquawkNews
Revenue: $6.91B (est $6.89B) Operating Income: $475M Adjusted EBITDA: $1.10B Paramount+ Revenue: +16% Y/Y Sees Q3 Revenue: $6.95B To $7.15B Sees Q3 Adjusted EBITDA: $875M To $975M Sees FY Revenue: $30.0B Sees FY Adjusted EBITDA: $3.80B To $3.90B Fully Expects Warner Bros. Transaction To Close
08:17:59 PM UTC
SquawkNews
Gilead Sciences Q2 26 Earnings
Revenue: $7.80B (est $7.40B) Adjusted Loss/Share: $6.75 (est loss/share $7.17) Trodelvy Revenue: $457M (est $423.2M) Biktarvy Revenue: $3.77B (est $3.60B) Veklury Revenue: $23M (est $98.1M) Sees FY Product Sales: $30.1B To $30.4B (est $30.06B) Sees FY Adjusted Loss/Share: 30c To 65c Sees FY Veklury Revenue: $300M, Saw $600M